Български (България)English (United Kingdom)
Българска Асоциация Диабет
http://www.badiabet.com/components/com_gk2_photoslide/images/thumbm/9163271.png http://www.badiabet.com/components/com_gk2_photoslide/images/thumbm/3261062.png http://www.badiabet.com/components/com_gk2_photoslide/images/thumbm/9529923.png http://www.badiabet.com/components/com_gk2_photoslide/images/thumbm/1547604.png http://www.badiabet.com/components/com_gk2_photoslide/images/thumbm/4997225.png
Print E-mail

Stimulate ß-cells are divided and successfully influenced the treatment of diabetes
27  January, 2009


Novocell leading biotech company has signed a two-year agreement with pharmaceutical giant Pfizer for the study of new methods to treat diabetes by turning embryonic stem cells into insulin-producing cells. The news was reported by Xconomy, San Diego. Pfizer company will use technology developed by Novocell for differentiation of embryonic stem cells into fully functional pancreatic beta-cells in order to produce the drugs for patients with diabetes, says the publication.
"Part of our strategy is to expand cooperation between academia and biotech companies. Our goal is to use the best scientific advances in new therapies, "says Katherine Makkiy representative of Pfizer. Months before the company have disclosed that they have equipped centers for stem-cell research, is located in the Cambridge, UK and Cambridge, Massachusetts. Novocell in turn will benefit and agreed cooperation with world-famous scientist Shaynaya Yamanaka of the University of Kyoto, Japan. It is notable that created pluripotentni stem cells induced by the initial models of mouse and subsequently from human skin tissue. Characteristic of these cells is that they have the potential of embryonic stem cells and provide the beginning of all 200 cell types in the body. Cultivated in a suitable environment can be converted into dopamine neurons that are suitable for the study and treatment of Parkinson's disease or pancreatic beta-cells to overcome diabetes. It is believed that the transplant induced pluripotentni stem cells do not bear the risk of rejection by the immune system of the body.
Last year, the interest of large pharmaceutical companies to work with stem cells is significantly increased. On the one hand, they help small biotechnology companies to survive and the other to prepare for rapid development of therapeutic programs based on research with stem cells. Data from recent months in this area are optimistic.
For more information about stem cells, you can call the tel.02/989 44 00 or www.cryo-save.com